A major shift in U.S. drug pricing policy was unveiled, with the administration pledging to align domestic medication costs with the lowest rates charged by other wealthy nations. The move, framed as a "most-favored nation" approach, aims to reduce expenses for American consumers by tying prices to international benchmarks. The White House emphasized the decision as a step toward addressing long-standing concerns over affordability in the healthcare system. Details on implementation and potential savings remain under scrutiny as stakeholders weigh the implications.
Under the most-favored nation agreement the president announced Monday, drug prices in the United States will be in line with the lowest prices paid by other developed nations, the White House said.
